Be a part of a new era
in cellular therapy

for the potential treatment of relapsed/refractory AML

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite advances in the management of AML, additional therapies are needed to overcome the limitations of current therapies, including treatments no longer working and overall toxicity of therapies.

Rubius Therapeutics is developing an investigational potential treatment option, RTX-240, for relapsed acute myeloid leukemia or refractory AML using the body’s own immune system to attack cancer. RTX-240 is an engineered red blood cell that is designed to activate the immune system against cancer.

About RTX-240
RTX-240 is an investigational cellular therapy that aims to activate the immune system to fight cancer.

RTX-240 is an engineered red blood cell that is being evaluated in a Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

RTX-240 is an investigational cellular therapy that is designed to activate and amplify the effects of immune system cells called natural killer (NK) cells and T cells, which play a role in killing tumor cells. The Phase 1/2 clinical study of RTX-240 has two arms – one in all solid tumors and one in relapsed AML or refractory AML.

Learn more about RTX-240